研究と業績　2021年

研究と業績　2021年

英文

  1. Nishimura S, Sugimoto A, Kushiyama S, Togano S, Kuroda K, Yamamoto Y, Yamauchi M, Sumi T, Kaneda H, Kawaguchi T, Kato M, Tagami M, Oebisu N, Hoshi M, Kimura K, Kubo S, Muguruma K, Takashima T, Ohira M, Yashiro M. Clinical benefit for clinical sequencing using cancer panel testing. PLoS One 2021;16:e0247090.
  2. Takahashi M, Takahashi K, Kaneda H, Kawaguchi T, Nagayama K. Pretreatment Platelet Count and Neutrophil/Lymphocyte Ratio Are Predictive Markers for Carboplatin Plus Pemetrexed Therapy-induced Thrombocytopenia. Anticancer Res 2021;41:5729-5737.
  3. Izumi M, Oyanagi J, Sawa K, Fukui M, Ogawa K, Matsumoto Y, Tani Y, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Ohsawa M, Yamamoto N, Koh Y, Kawaguchi T. Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors. Sci Rep 2021;11:5680.
  4. Izumi M, Sawa K, Oyanagi J, Noura I, Fukui M, Ogawa K, Matsumoto Y, Tani Y, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Nishiyama N, Ohsawa M, Yamamoto N, Koh Y, Kawaguchi T. Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Transl Oncol 2021;14:101102.
  5. Yoshimura N, Sawa K, Nakai T, Matsumoto Y, Mitsuoka S, Kimura T, Asai K, Yana T, Kawaguchi T, Hirata K. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer. Clinical Trial Am J Clin Oncol 2021;44:613-618.
  6. Kaneda H, Sawa K, Daga H, Okada A, Nakatani Y, Atagi S, Okishio K, Tani Y, Matsumoto Y, Ogawa K, Nakahama K, Izumi M, Mitsuoka S, Kawaguchi T. Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases. Clinical Trial Invest New Drugs 2021;39:1598-1603.
  7. Kato R, Hayashi H, Sakai K, Suzuki S, Haratani K, Takahama T, Tanizaki J, Nonagase Y, Tanaka K, Yoshida T, Takeda M, Yonesaka K, Kaneda H, Nishio K, Nakagawa K. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after Osimertinib. Int J Clin Oncol 2021;26:1628-1639.
  8. Oku A, Nakai K, Ikenaga T, Sato K, Mitsuoka S, Takahashi S, Tanoue K, Sawada A, Nagami Y, Tsuruta D. Case of afatinib-induced severe purpuric drug eruption with gastrointestinal bleeding. J Dermatol 2021;48:e534-e535.
  9. Katayama H, Mizusawa J, Fukuda H, Nakamura S, Nakamura K, Saijo N, Yokoyama A, Ohe Y, Shinkai T, Nakagawa K, Abe T, Mitsuoka S, Okamoto H, Yamamoto N, Yoshioka H, Ando M, Tamura T, Takeda K. Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A). Jpn J Clin Oncol 2021;51:685-692.
  10. Nakako S, Nakashima Y, Okamura H, Tani Y, Ueda T, Makuuchi Y, Kuno M, Takakuwa T, Nishimoto M, Koh H, Nakamae H, Hino M. Delayed immune-related neutropenia with hepatitis by pembrolizumab. Immunotherapy 2022;14:101-105.